immune checkpoint inhibitor

You have access
RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression
HIROAKI NAGAMINE, MASAKAZU YASHIRO, NAOKI YOSHIMOTO, MOTOHIRO IZUMI, AKIRA SUGIMOTO, KENJI NAKAHAMA, KOICHI OGAWA, YOSHIYA MATSUMOTO, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, KAZUHIRO YAMADA, TETSUYA WATANABE, KAZUHISA AASAI, KAZUHIRO FUKUMURA, AKILA MAYEDA and TOMOYA KAWAGUCHI

Anticancer Research October 2023, 43 (10) 4663-4672; DOI: https://doi.org/10.21873/anticanres.16662
You have access
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, MIRII HARADA, SHINGO TAMURA, HIROKI KOBAYASHI, KAEDE MORIHARA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA

Anticancer Research October 2023, 43 (10) 4701-4708; DOI: https://doi.org/10.21873/anticanres.16666
You have access
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

Anticancer Research June 2023, 43 (6) 2717-2724; DOI: https://doi.org/10.21873/anticanres.16438
You have access
Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
HYERA KIM, DONG HYUN LIM, YONG SHIK KWON, MI AE KIM and KEON UK PARK

Anticancer Research May 2023, 43 (5) 2343-2349; DOI: https://doi.org/10.21873/anticanres.16399
Open Access
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG

Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
You have access
Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI

Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
You have access
Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
NAR BAHADUR KATUWAL, NAHEE PARK, KAMAL PANDEY, MIN SIL KANG, SA DEOK HONG, MITHUN GHOSH, SEUL-GI KIM, YOUNG BIN CHO, JIN HUR, SEUNG KI KIM and YONG WHA MOON

Anticancer Research January 2023, 43 (1) 85-95; DOI: https://doi.org/10.21873/anticanres.16137
You have access
Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation
SOU HATTORI, SHINICHIRO OKAUCHI, YUIKA SASATANI, GEN OHARA, KUNIHIKO MIYAZAKI, SHINYA SATO, TAKAHIDE KODAMA, TOSHIHIRO SHIOZAWA, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research September 2022, 42 (9) 4589-4595; DOI: https://doi.org/10.21873/anticanres.15962
You have access
Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO

Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
You have access
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA

Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854

Main menu

User menu

Search

immune checkpoint inhibitor

Pages